Podium to Practice: ESMO® 2025 – BREAST: OptiTROP-Breast02

Podium to Practice: ESMO® 2025 – BREAST: OptiTROP-Breast02

Podium to Practice: ESMO® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Christine Simmons

Icon Chair Speaker

Speakers

Dr. Christine Brezden-Masley

Dr. Heather McArthur

Studies / Trials Discussed

LBA23 – Sacituzumab tirumotecan (sac-TMT) vs investigator’s choice of chemotherapy (ICC) in previously treated locally advanced or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Results from the randomized, multi-center phase III OptiTROP-Breast02 study

Studies/trials discussed:

LBA23 – Sacituzumab tirumotecan (sac-TMT) vs investigator’s choice of chemotherapy (ICC) in previously treated locally advanced or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Results from the randomized, multi-center phase III OptiTROP-Breast02 study
Tagged